Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.56 |
| ▸ | MAOB | P27338 | 3/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.47 |
| ▸ | DPP4 | P27487 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | ICMT | O60725 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10607505 | 0.91 | DPP4 (0.53) | MAOAMAOBTAAR1OPRM1OPRL1 | |
| SCHEMBL2089640 | 0.90 | SLC6A4 (0.59) | MAOAMAOBTAAR1DPP4SLC6A4 | |
| SCHEMBL27874183 | 0.87 | OPRM1 (0.53) | MAOAMAOBTAAR1OPRM1OPRL1 | |
| SCHEMBL21770897 | 0.86 | TACR1 (0.53) | MAOAMAOBTAAR1OPRM1SLC6A4 | |
| SCHEMBL13265659 | 0.86 | ICMT (0.54) | MAOAMAOBTAAR1OPRM1DPP4 | |
| SCHEMBL21273774 | 0.85 | OPRM1 (0.49) | MAOAMAOBTAAR1OPRM1SLC6A4 | |
| SCHEMBL15955086 | 0.81 | MAOA (0.60) | MAOAMAOBTAAR1OPRM1OPRL1 | |
| SCHEMBL29201208 | 0.80 | SLC6A4 (0.42) | MAOAMAOBTAAR1DPP4SLC6A4 | |
| SCHEMBL10608925 | 0.79 | OPRM1 (0.50) | MAOAMAOBTAAR1OPRM1OPRL1 | |
| SCHEMBL14415547 | 0.79 | SLC6A2 (0.56) | MAOAMAOBTAAR1OPRM1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1686995-A1 | USE OF CATHEPSIN K INHIBITORS FOR TREATING OF SEVERE BONE LOSS DISEASES | Novartis AG (CH) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005049028-A1 | USE OF CATHEPSIN K INHIBITORS IN SEVERE BONE LOSS DISEASES | NOVARTIS AG (CH) | 2005-06-02 | — | — | WO | disclosed |